Literature DB >> 32920865

Poorly differentiated chordoma with whole-genome doubling evolving from a SMARCB1-deficient conventional chordoma: A case report.

Christian Curcio1, Robert Cimera2, Ruth Aryeequaye2, Mamta Rao2, Nicola Fabbri3, Yanming Zhang2, Meera Hameed2.   

Abstract

Evolution of poorly differentiated chordoma from conventional chordoma has not been previously reported. We encountered a case of a poorly differentiated chordoma with evidence of whole-genome doubling arising from a SMARCB1-deficient conventional chordoma. The tumor presented as a destructive sacral mass in a 43-year-old man and was comprised of a highly cellular poorly differentiated chordoma with small, morphologically distinct nodules of conventional chordoma accounting for <5% of the total tumor volume. Immunohistochemistry (IHC) revealed both components were strongly reactive for brachyury and lacked normal staining for INI1. Single nucleotide polymorphism (SNP) array analysis identified multiple genomic imbalances in the conventional component, including deletions of 1p, 3p, and 22q (involving SMARCB1) and loss of chromosomes 5 and 15, while the poorly differentiated component exhibited the same aberrations at a more profound level with additional loss of chromosome 4, low level focal deletion of 17p (involving TP53), and tetraploidy. Homozygous deletion of SMARCB1 was present in both components. Fluorescence in situ hybridization (FISH) analysis confirmed the relevant deletions in both components as well as genome doubling in the poorly differentiated tumor. This case suggests that SMARCB1 loss is an early event in rare conventional chordomas that could potentially evolve into poorly differentiated chordoma through additional genomic aberrations such as genome doubling. Further studies with additional patients will be needed to determine if genome doubling is a consistent pathway for evolution of poorly differentiated chordoma.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  SMARCB1; conventional chordoma; poorly differentiated chordoma; whole-genome doubling

Mesh:

Substances:

Year:  2020        PMID: 32920865      PMCID: PMC7755306          DOI: 10.1002/gcc.22895

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  21 in total

1.  Dedifferentiated Chordoma: Clinicopathologic and Molecular Characteristics With Integrative Analysis.

Authors:  Yin P Hung; Julio A Diaz-Perez; Gregory M Cote; Johan Wejde; Joseph H Schwab; Valentina Nardi; Ivan A Chebib; Vikram Deshpande; Martin K Selig; Miriam A Bredella; Andrew E Rosenberg; G Petur Nielsen
Journal:  Am J Surg Pathol       Date:  2020-09       Impact factor: 6.394

2.  Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.

Authors:  Sarah K Knutson; Natalie M Warholic; Tim J Wigle; Christine R Klaus; Christina J Allain; Alejandra Raimondi; Margaret Porter Scott; Richard Chesworth; Mikel P Moyer; Robert A Copeland; Victoria M Richon; Roy M Pollock; Kevin W Kuntz; Heike Keilhack
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-25       Impact factor: 11.205

Review 3.  Poorly differentiated chordoma: review of 53 cases.

Authors:  H Gokce Yeter; Kemal Kosemehmetoglu; Figen Soylemezoglu
Journal:  APMIS       Date:  2019-09       Impact factor: 3.205

Review 4.  Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases.

Authors:  G F Fleming; P S Heimann; J K Stephens; M A Simon; M K Ferguson; R S Benjamin; B L Samuels
Journal:  Cancer       Date:  1993-08-01       Impact factor: 6.860

5.  Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis.

Authors:  Martin Hasselblatt; Christian Thomas; Volker Hovestadt; Daniel Schrimpf; Pascal Johann; Susanne Bens; Florian Oyen; Susanne Peetz-Dienhart; Yvonne Crede; Annika Wefers; Hannes Vogel; Markus J Riemenschneider; Manila Antonelli; Felice Giangaspero; Marie Christine Bernardo; Caterina Giannini; Nasir Ud Din; Arie Perry; Kathy Keyvani; Frank van Landeghem; David Sumerauer; Peter Hauser; David Capper; Andrey Korshunov; David T W Jones; Stefan M Pfister; Reinhard Schneppenheim; Reiner Siebert; Michael C Frühwald; Marcel Kool
Journal:  Acta Neuropathol       Date:  2016-04-11       Impact factor: 17.088

Review 6.  Chordoma: the entity.

Authors:  Youssef Yakkioui; Jacobus J van Overbeeke; Remco Santegoeds; Manon van Engeland; Yasin Temel
Journal:  Biochim Biophys Acta       Date:  2014-09-03

7.  Prognostic value of MIB-1, p53, epidermal growth factor receptor, and INI1 in childhood chordomas.

Authors:  Rajni Yadav; Mehar Chand Sharma; Prit Benny Malgulwar; Pankaj Pathak; Elanthenral Sigamani; Vaishali Suri; Chitra Sarkar; Amandeep Kumar; Manmohan Singh; Bhawani Shankar Sharma; Ajay Garg; Sameer Bakhshi; Mohammed Faruq
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

8.  Genomic aberrations frequently alter chromatin regulatory genes in chordoma.

Authors:  Lu Wang; Ahmet Zehir; Khedoudja Nafa; Nengyi Zhou; Michael F Berger; Jacklyn Casanova; Justyna Sadowska; Chao Lu; C David Allis; Mrinal Gounder; Chandhanarat Chandhanayingyong; Marc Ladanyi; Patrick J Boland; Meera Hameed
Journal:  Genes Chromosomes Cancer       Date:  2016-05-09       Impact factor: 5.006

9.  Chordoma characterization of significant changes of the DNA methylation pattern.

Authors:  Beate Rinner; Andreas Weinhaeusel; Birgit Lohberger; Elke Verena Froehlich; Walter Pulverer; Carina Fischer; Katharina Meditz; Susanne Scheipl; Slave Trajanoski; Christian Guelly; Andreas Leithner; Bernadette Liegl
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

10.  Genome doubling shapes the evolution and prognosis of advanced cancers.

Authors:  Craig M Bielski; Ahmet Zehir; Alexander V Penson; Mark T A Donoghue; Walid Chatila; Joshua Armenia; Matthew T Chang; Alison M Schram; Philip Jonsson; Chaitanya Bandlamudi; Pedram Razavi; Gopa Iyer; Mark E Robson; Zsofia K Stadler; Nikolaus Schultz; Jose Baselga; David B Solit; David M Hyman; Michael F Berger; Barry S Taylor
Journal:  Nat Genet       Date:  2018-07-16       Impact factor: 38.330

View more
  1 in total

1.  Recurrent loss of chromosome 22 and SMARCB1 deletion in extra-axial chordoma: A clinicopathological and molecular analysis.

Authors:  Xiaoyun Wen; Robert Cimera; Ruth Aryeequaye; Mohanty Abhinta; Edward Athanasian; John Healey; Nicola Fabbri; Patrick Boland; Yanming Zhang; Meera Hameed
Journal:  Genes Chromosomes Cancer       Date:  2021-08-26       Impact factor: 5.006

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.